A case of atopic cough with aphonia showed a prominent response to a histamine H1 receptor antagonist

J Med Invest. 2023;70(1.2):281-284. doi: 10.2152/jmi.70.281.

Abstract

A 33-year-old woman admitted to our hospital for further examination of severe non-productive cough lasting for about two months. Her symptom did not ameliorate by treatments including long acting β2 agonists. She had a medical history of drug allergy to non-steroidal anti-inflammatory drugs. At the initial visit, she could not speak at all and communicated with us in writing. Chest auscultation revealed no wheezes, rhonchi and other crackles. Laboratory findings showed a mild eosinophilia with normal total and specific serum immunoglobulin E. The results of an electrocardiogram, a chest X-ray and a chest CT were unremarkable. A fractional exhaled nitric oxide value was within normal limit. Based on these observations, a diagnosis of atopic cough (AC) was suspected, and we started treatment with a histamine H1 receptor antagonist (H1-RA). She had become able to speak again in association with complete disappearance of cough by eight-weeks after treatment initiation, and her symptoms did not recur even after cessation of treatment. By the confirmation of remarkable clinical improvement in response to a H1-RA, a diagnosis of AC was made. To the best of our knowledge, this is the first report of an AC patient who presented severe cough with aphonia. J. Med. Invest. 70 : 281-284, February, 2023.

Keywords: aphonia; atopic cough; bronchodilator resistant chronic cough; histamine H1 receptor antagonist.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Aphonia / complications
  • Aphonia / drug therapy
  • Cough* / drug therapy
  • Cough* / etiology
  • Female
  • Histamine H1 Antagonists* / therapeutic use
  • Humans

Substances

  • Histamine H1 Antagonists